Watch: The abandonment of Biogen’s Alzheimer’s drug, which cost it $18 billion in market value, follows the failure of similar efforts by others. rob_cyran explains why investors may have been too optimistic.
The abandonment of Biogen’s Alzheimer’s drug, which cost it $18 billion in market value, follows the failure of similar efforts by others. It’s a potentially huge market, but a tough one to crack. Rob Cyran explains why investors may have been too optimistic.
The abandonment of Biogen’s Alzheimer’s drug, which cost it $18 billion in market value, follows the failure of similar efforts by others. It’s a potentially huge market, but a tough one to crack. Rob Cyran explains why investors may have been too optimistic.https://reut.rs/2ulzzdH
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Breakingviews TV: Google’s fineWatch: European authorities hit Google with a fresh penalty for abusing its dominance. rob_cyran explains that nearly $10 bln in collective fines pale beside the company’s $600 bln increase in market cap, which suggests regulators may need bigger sticks.
Weiterlesen »
Breakingviews TV: K-pop idlesAfter scandal enveloped a member of South Korean boy band Big Bang, shares in the industry’s talent agencies plummeted this week. Robyn Mak and Jeffrey Goldfarb discuss how YouTube and Spotify should be able to help the popular music export pick up...
Weiterlesen »
Breakingviews TV: Heavy LyftThe ride-hailing company seeks a valuation of up to $23 bln with its public offering. Lyft has first-mover advantage over Uber, but as Richard Beales explains, supervoting shares for the founders and no clear path to profitability pose tough...
Weiterlesen »
Biogen scraps Alzheimer drug trials, wiping $17 billion off its market valueReuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for t...
Weiterlesen »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
Weiterlesen »
Biogen loses same Alzheimer’s bet others have lostThe failures of similar drugs in formal trials meant Biogen’s effort was always a long shot. Yet ditching it vaporized $18 bln, or over a quarter, of the biotech’s value. The giant market for a therapy and the fear of missing out lured in both the company and Wall Street.
Weiterlesen »
Stocks making the biggest moves midday: Levi Strauss, Biogen, Micron & moreThese are the stocks posting the largest moves midday Thursday.
Weiterlesen »
Biogen heads for the worst day in a decade after ending trial for blockbuster Alzheimer's drugShares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab.
Weiterlesen »
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
Weiterlesen »